You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
CASE REPORT
The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD)
  1. Jun Shoji,
  2. Susie Q Lew
  1. Department of Medicine, George Washington University, Washington, DC, USA
  1. Correspondence to Dr Susie Q Lew, sqlew{at}gwu.edu

Summary

A patient with a history of type 2 diabetes mellitus and chronic lymphocytic leukaemia has renal failure with large kidneys. The patient refused kidney biopsy to determine the aetiology of her renal failure. She uses peritoneal dialysis to treat renal failure. She received rituximab and bendamustine to treat chronic lymphocytic leukaemia. Adenopathy resolves with treatment and she does not experience any electrolyte disturbances or decrease in urine output as a result of chemotherapy in the setting of renal failure. Renal function did not recover with chemotherapy.

https://doi.org/10.1136/bcr-2013-009637

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Linked Articles

    • Correction
      BMJ Publishing Group Ltd
      Case Reports 2014; 2014 - Published Online First: 02 Jan 2014. doi: 10.1136/bcr-2013-009637corr1